Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Pembrolizumab Plus Lenvatinib Improves Survival in dMMR Endometrial Cancer

September 7th 2021

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.

Dr. Eskander on the Utility of Lymphadenectomy in Endometrial Cancer

August 25th 2021

Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.

Transvaginal Ultrasound Misses Mark on Screening Endometrial Cancer in Black Women

August 20th 2021

The use of transvaginal ultrasonography to measure the need for diagnostic testing of endometrial cancer missed almost 5 times more endometrial cancer cases in Black women compared with those in White women.

Dr. Robert L. Coleman discusses Rubraca® (rucaparib) for 2L Maintenance Treatment

August 18th 2021

FDA Green Lights First Companion Diagnostic for Dostarlimab in dMMR Solid Tumors

August 18th 2021

The FDA has approved the VENTANA MMR RxDx panel as the first companion diagnostic test to assist in identifying patients with solid tumors that are DNA mismatch repair deficient who may be eligible to receive the anti–PD-1 therapy dostarlimab-gxly, which was recently granted an accelerated approval by the agency.

FDA Grants Fast Track Designation to STRO-002 for Advanced Ovarian Cancer

August 18th 2021

The FDA has granted a fast track designation to STRO-002 as a potential therapeutic option for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received 1 to 3 lines of systemic therapy.

FDA Approves Dostarlimab-gxly for dMMR Recurrent or Advanced Solid Tumors

August 17th 2021

The FDA has granted an accelerated approval to dostarlimab-gxly for the treatment of adult patients with mismatch repair-deficient recurrent or advanced solid tumors, as determined by an FDA-approved test, who have progressed on or following previous treatment and who have no satisfactory alternative options.

FDA Grants Fast Track Status to IN10018 for Platinum-Resistant Ovarian Cancer

August 16th 2021

The FDA has granted a fast track designation to IN10018 as a potential therapeutic option for use in patients with platinum-resistant ovarian cancer.

FDA Approval Sought for Single-Agent Pembrolizumab for Select MSI-H/dMMR Advanced Endometrial Carcinoma

August 10th 2021

The FDA has accepted a new supplemental biologics license application that is seeking the approval of pembrolizumab for use as a monotherapy in patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair deficient, who have progressed after systemic therapy in any setting and are not eligible for curative surgery or radiation.

FDA Grants Regular Approval to Pembrolizumab Plus Lenvatinib for Advanced Endometrial Carcinoma

July 22nd 2021

The FDA has granted a regular approval to pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression after previous systemic therapy in any setting, and who are not candidates for curative surgery or radiation.

Dostarlimab Expands Options for dMMR Endometrial Cancer

July 14th 2021

Patients with mismatch repair–deficient recurrent or advanced endometrial cancer gained an efficacious and safe treatment option with the addition of dostarlimab-gxly.

Personalized Medicine Is Gaining Momentum in Advanced Endometrial Cancer

July 9th 2021

Molecular characterization of endometrial tumors has resulted in a boom of investigative efforts aimed at ushering in a new era of tailored therapeutic regimens for patients with these malignancies.

Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers

July 5th 2021

Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.

Adjuvant Advances Shine at ASCO 2021

July 1st 2021

Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting

Coleman Centers the Discussion on Practice-Affirming ASCO Trials in Gynecologic Oncology

June 29th 2021

Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.

Frontline Pembrolizumab Plus Chemo With or Without Bevacizumab Improves Survival in Cervical Cancer

June 22nd 2021

Pembrolizumab plus platinum-based chemotherapy with or without bevacizumab significantly improved overall survival and progression-free survival over the same platinum-based chemotherapy regimen with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer—irrespective of PD-L1 status.

FDA Grants Priority Review to Balstilimab for Recurrent or Metastatic Cervical Cancer

June 17th 2021

The FDA has granted priority review to the biologics license application for balstilimab for use in the treatment of patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

Trastuzumab Duocarmazine Shows Superiority Over Physician’s Choice for HER2+ Breast Cancer

June 8th 2021

The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.

Pertuzumab/Trastuzumab Combo Elicits Clinical Activity in ERBB2/ERBB3+ Uterine Cancer

June 7th 2021

The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer.

Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane

June 7th 2021

OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.